Last reviewed · How we verify

NCT04578301: PERSEVERE

Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease

Recruiting now Last updated 18 May 2022
What this trial tests

trial testing No Intervention in Liver Cirrhosis in 200 participants. Currently enrolling.

Timeline
22 September 2020
Primary endpoint
31 December 2025
31 December 2026

Quick facts

Lead sponsorUniversity Hospital, Bonn
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date22 September 2020
Primary completion31 December 2025
Estimated completion31 December 2026
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bonn

Who can join

18 and older, any sex, with Liver Cirrhosis or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, observational study to define precipitants and predictors of development of Acute-on-Chronic Liver Failure (ACLF) after surgical interventions, allowing to develop a risk stratification for elective procedures in cirrhotic patients. As well as identifying molecular mechanisms of post-interventional ACLF and thus preparing the ground for development of new therapeutic approaches.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other University Hospital, Bonn trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04578301.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing